Previous 10 | Next 10 |
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown , President and Chief Executive...
2023-12-07 15:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today we're highlighting November 2023 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ...
2023-11-13 18:50:25 ET DURECT Corporation (DRRX) Q3 2023 Earnings Conference Call November 13, 2023, 04:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Conference Call Participants François Brisebo...
2023-11-13 16:08:14 ET More on DURECT DURECT: Reading Into AHFIRM Mortality Rates HC Wainwright downgrades DURECT to neutral, removes price target Durect plummets as lead asset fails in mid-stage trial for liver disorder Seeking Alpha’s Quant Rating on...
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update PR Newswire - Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET - Topline data from AHFIRM trial showed compelling efficacy signal in favor of lars...
2023-11-13 07:12:29 ET Summary On Nov 7, DURECT announced topline results from AHFIRM, a phase 2 randomized, placebo-controlled trial studying larsucosterol for severe alcohol-associated hepatitis (AH). The trial did not meet the primary endpoint, i.e. statistically-significant be...
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif. , Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of ...
2023-11-08 14:30:27 ET More on DURECT Durect plummets as lead asset fails in mid-stage trial for liver disorder Northland sees DURECT's upcoming data as "major" catalyst for stock (update) Seeking Alpha’s Quant Rating on DURECT Historical earnings data...
2023-11-08 13:40:12 ET Gainers: Tenon Medical ( TNON ) +37% . Blade Air Mobility ( BLDE ) +32% . Novo Integrated Sciences ( NVOS ) +29%. Therealreal ( REAL ) +27% . ShiftPixy ( PIXY ) +20% . American Public Education ( APEI )...
2023-11-08 10:00:55 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in For further details see: Durect, Lumos Pharma among healthcare movers
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif. , May 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development...